
Synthetic glycan-based TLR4 agonists targeting caspase-4/11 for the development of adjuvants and immunotherapeutics
- Author
- Florian Adanitsch, Jianjin Shi, Feng Shao, Rudi Beyaert (UGent) , Holger Heine and Alla Zamyatina
- Organization
- Abstract
- Gram-negative bacterial lipopolysaccharide (LPS)-induced Toll-like receptor 4 (TLR4) mediated pro-inflammatory signaling plays a key role in immunoprotection against infectious challenges and boosts adaptive immunity, whereas the activation of the cytosolic LPS receptor caspase-4/11 leads to cell death by pyroptosis and is deeply implicated in the development of sepsis. Despite tremendous advances in the understanding of the LPS-TLR4 interaction, predictably regulated TLR4 activation has not yet been achieved. The structural basis for the induction of caspase-4/11 protease activity by LPS is currently unknown. The modulation of innate and adaptive immune responses through the controlled induction of TLR4 signaling without triggering caspase-4/11 activity would open novel perspectives in the development of safe vaccine adjuvants and immunotherapeutics. We report the discovery of highly potent glycan-based immunostimulants with picomolar affinity for TLR4 which interact with caspase-4/11 and promote caspase-4/11 oligomerization while abolishing caspase-11 protease activity. The rigidity and twisted molecular shape of the alpha,alpha-(1 <--> 1')-linked disaccharide core of synthetic LPS mimicking anionic glycolipids accounted for both species-independent and adjustable TLR4-mediated NF-kappa B signaling and the modulation of caspase-4/11 activation. By the use of crystal structure based design and advanced synthetic chemistry we created a set of versatile probes for studying the structural basis of caspase-4/11 activation and established a chemical strategy for controllable TLR4 mediated cytokine release which is dissociable from the induction of caspase-11 protease activity.
- Keywords
- TOLL-LIKE RECEPTORS, MONOPHOSPHORYL-LIPID-A, INNATE IMMUNE RECEPTORS, INFLAMMATORY CASPASES, STRUCTURAL BASIS, VACCINE ADJUVANT, TLR4/MD-2, ACTIVATION, ALZHEIMERS-DISEASE, INTRACELLULAR LPS, ENDOTOXIN
Downloads
-
3059 18Adanitsch.pdf
- full text
- |
- open access
- |
- |
- 1.32 MB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-8582072
- MLA
- Adanitsch, Florian, et al. “Synthetic Glycan-Based TLR4 Agonists Targeting Caspase-4/11 for the Development of Adjuvants and Immunotherapeutics.” CHEMICAL SCIENCE, vol. 9, no. 16, 2018, pp. 3957–63, doi:10.1039/c7sc05323a.
- APA
- Adanitsch, F., Shi, J., Shao, F., Beyaert, R., Heine, H., & Zamyatina, A. (2018). Synthetic glycan-based TLR4 agonists targeting caspase-4/11 for the development of adjuvants and immunotherapeutics. CHEMICAL SCIENCE, 9(16), 3957–3963. https://doi.org/10.1039/c7sc05323a
- Chicago author-date
- Adanitsch, Florian, Jianjin Shi, Feng Shao, Rudi Beyaert, Holger Heine, and Alla Zamyatina. 2018. “Synthetic Glycan-Based TLR4 Agonists Targeting Caspase-4/11 for the Development of Adjuvants and Immunotherapeutics.” CHEMICAL SCIENCE 9 (16): 3957–63. https://doi.org/10.1039/c7sc05323a.
- Chicago author-date (all authors)
- Adanitsch, Florian, Jianjin Shi, Feng Shao, Rudi Beyaert, Holger Heine, and Alla Zamyatina. 2018. “Synthetic Glycan-Based TLR4 Agonists Targeting Caspase-4/11 for the Development of Adjuvants and Immunotherapeutics.” CHEMICAL SCIENCE 9 (16): 3957–3963. doi:10.1039/c7sc05323a.
- Vancouver
- 1.Adanitsch F, Shi J, Shao F, Beyaert R, Heine H, Zamyatina A. Synthetic glycan-based TLR4 agonists targeting caspase-4/11 for the development of adjuvants and immunotherapeutics. CHEMICAL SCIENCE. 2018;9(16):3957–63.
- IEEE
- [1]F. Adanitsch, J. Shi, F. Shao, R. Beyaert, H. Heine, and A. Zamyatina, “Synthetic glycan-based TLR4 agonists targeting caspase-4/11 for the development of adjuvants and immunotherapeutics,” CHEMICAL SCIENCE, vol. 9, no. 16, pp. 3957–3963, 2018.
@article{8582072, abstract = {{Gram-negative bacterial lipopolysaccharide (LPS)-induced Toll-like receptor 4 (TLR4) mediated pro-inflammatory signaling plays a key role in immunoprotection against infectious challenges and boosts adaptive immunity, whereas the activation of the cytosolic LPS receptor caspase-4/11 leads to cell death by pyroptosis and is deeply implicated in the development of sepsis. Despite tremendous advances in the understanding of the LPS-TLR4 interaction, predictably regulated TLR4 activation has not yet been achieved. The structural basis for the induction of caspase-4/11 protease activity by LPS is currently unknown. The modulation of innate and adaptive immune responses through the controlled induction of TLR4 signaling without triggering caspase-4/11 activity would open novel perspectives in the development of safe vaccine adjuvants and immunotherapeutics. We report the discovery of highly potent glycan-based immunostimulants with picomolar affinity for TLR4 which interact with caspase-4/11 and promote caspase-4/11 oligomerization while abolishing caspase-11 protease activity. The rigidity and twisted molecular shape of the alpha,alpha-(1 <--> 1')-linked disaccharide core of synthetic LPS mimicking anionic glycolipids accounted for both species-independent and adjustable TLR4-mediated NF-kappa B signaling and the modulation of caspase-4/11 activation. By the use of crystal structure based design and advanced synthetic chemistry we created a set of versatile probes for studying the structural basis of caspase-4/11 activation and established a chemical strategy for controllable TLR4 mediated cytokine release which is dissociable from the induction of caspase-11 protease activity.}}, author = {{Adanitsch, Florian and Shi, Jianjin and Shao, Feng and Beyaert, Rudi and Heine, Holger and Zamyatina, Alla}}, issn = {{2041-6520}}, journal = {{CHEMICAL SCIENCE}}, keywords = {{TOLL-LIKE RECEPTORS,MONOPHOSPHORYL-LIPID-A,INNATE IMMUNE RECEPTORS,INFLAMMATORY CASPASES,STRUCTURAL BASIS,VACCINE ADJUVANT,TLR4/MD-2,ACTIVATION,ALZHEIMERS-DISEASE,INTRACELLULAR LPS,ENDOTOXIN}}, language = {{eng}}, number = {{16}}, pages = {{3957--3963}}, title = {{Synthetic glycan-based TLR4 agonists targeting caspase-4/11 for the development of adjuvants and immunotherapeutics}}, url = {{http://doi.org/10.1039/c7sc05323a}}, volume = {{9}}, year = {{2018}}, }
- Altmetric
- View in Altmetric
- Web of Science
- Times cited: